Elpiscience

Choose Language : EN

EN CN

EN | CN

Harnessing IMMUNOLOGY to Fight Cancer

OUR COMPANY

... capitalizes on the latest biology break-throughs to innovate and develop the next generation of cancer immunotherapies ...

ES101, a First in Class Molecule in Phase I Clinical Trial

view more

NEWS RELEASE

TRIGR Therapeutics and Elpiscience Biopharmaceuticals Announce $117 Million Exclusive China Licensing Transaction for TR009, a Phase 1B Dual Angiogenic Bispecific Antibody Targeting DLL4/VEGF
2021-01-20
IRVINE, CA and SHANGHAI, China, January 20, 2021 TRIGR Therapeutics, Inc. (“TRIGR”), a US based clinical stage biopharmaceutical company focused on the development of multi-targ...
Elpiscience to Present at 39th Annual J.P. MORGAN Healthcare Conference
2021-01-11
Shanghai, China, January 11th 2021. Elpiscience Biopharma Ltd., a clinical stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies...

view more

Our Science